Active ingredientMolidustatCat. No. P-M158-001CAS 1154028-82-6Family · Pharmaceutical analytical standards
Molidustat
An oral inhibitor of HIF prolyl hydroxylase: it mimics a lack of oxygen and prompts the body to produce its own erythropoietin. Approved in Japan in 2021 for anaemia of chronic kidney disease. This family brings together the active ingredient and metabolites.
Did you know?In 2023 it also received conditional approval in the United States as a veterinary drug, for anaemia in cats with chronic kidney disease.
Go to the active ingredient →Active ingredientMolidustatCat. No. P-M158-001CAS 1154028-82-6
Active ingredientMolidustat Sodium SaltCat. No. P-M158-002CAS 1375799-59-9
MetaboliteMolidustat GlucuronideCat. No. P-M158-003CAS 2230205-31-7No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.